T2C2 CAPITAL
T2C2 (Technology, Transfer, Commercialisation, Capital) has the mission to identify in Universities, Research Centres and Industry, business opportunities and turn them into real businesses. Outstanding science, high-quality entrepreneurs, intellectual property and commercial potential are the key elements and criteria that are used to select projects. T2C2 gets involved in the seed phase to support the continuation of the research and to develop the business engineering of the project. Following the seed phase, T2C2 participates with other investors in the financing of the following rounds.
T2C2 CAPITAL
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Domain Not Resolving Amap
Similar Organizations
University of Tuebingen
Tuebingen University is a German public research university.
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2006-10-25 | Cytheris | T2C2 Capital investment in Series B - Cytheris | 30.7 M USD |
| 2006-07-24 | TransPharma Medical | T2C2 Capital investment in Series C - TransPharma Medical | 18 M USD |
| 2005-10-10 | Topigen Pharmaceuticals | T2C2 Capital investment in Series B - Topigen Pharmaceuticals | 6 M CAD |
| 2005-05-20 | BioAxone Therapeutic | T2C2 Capital investment in Series B - BioAxone Therapeutic | 12.15 M USD |
| 2005-01-18 | Enobia Pharma | T2C2 Capital investment in Series A - Enobia Pharma | 15.55 M USD |
| 2004-12-01 | Topigen Pharmaceuticals | T2C2 Capital investment in Venture Round - Topigen Pharmaceuticals | 22.6 M CAD |
| 2003-11-26 | Chronogen | T2C2 Capital investment in Series B - Chronogen | 17 M CAD |
| 2003-11-05 | IatroQuest Corporation | T2C2 Capital investment in Venture Round - IatroQuest Corporation | 15 M CAD |
| 2001-12-18 | Cytochroma | T2C2 Capital investment in Series B - Cytochroma | 3.5 M CAD |
| 2001-10-05 | Interomex BioPharmaceuticals | T2C2 Capital investment in Series B - Interomex BioPharmaceuticals | 4 M USD |